According to Juvenile Diabetes Research Foundation, an estimated 3 million Americans are living with type-1 diabetes (T1D), and as many as 80 people are diagnosed with diabetes in the US every day. Current assays employed in the detection of type-1 diabetes are expensive and time consuming, which is why Genalyte‘s new biomarker panel could be a much needed update to the detection process, utilizing Micro Ring sensors constructed using silicon photonic technology.
According to the diagnostics company, when used in conjunction with their fully automated Maverick Detection System, the multiplexed antigen panel can measure seven autoantibodies associated with the characteristic destruction of pancreatic islet cells associated with diabetes: Insulin, Proinsulin, GAD65, GAD67, IA-2, Phogrin, and ZnT8. The system directly monitors the binding of proteins and antibodies to to the sensor on the biomarker panel in real-time, and is said to provide results in as little as 15 minutes.The actual biomarker panel is disposable, requires only a 2μL sample, and according to Genalyte, “almost all of the most time consuming and expensive parts of assay development and sample testing are reduced or eliminated.”
Product Page: Maverick Type 1 Diabetes (T1D) Assay…
Technology overview: Multiplex Profiling of T1D Autoantibodies with Maverick, a Silicon Photonic Detection System… (.pdf)
